GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Braf | affects response to substance | ISO | BRAF (Homo sapiens) | 6480464 | CTD | BRAF protein affects the susceptibility to dabrafenib | PMID:29950559 | Braf | decreases activity | ISO | BRAF (Homo sapiens) | 6480464 | CTD | dabrafenib results in decreased activity of BRAF protein; dabrafenib results in decreased activity of BRAF protein mutant form | PMID:20823850 PMID:23237741 | Braf | increases response to substance | ISO | BRAF (Homo sapiens) | 6480464 | CTD | BRAF protein mutant form results in increased susceptibility to dabrafenib | PMID:26978007 | Braf | multiple interactions | ISO | BRAF (Homo sapiens) | 6480464 | CTD | [BRAF protein affects the susceptibility to dabrafenib] which affects the cleavage of SREBF1 protein; betulin affects the reaction [BRAF protein affects the susceptibility to [dabrafenib co-treated with trametinib]]; BRAF protein affects the susceptibility to [dabrafenib co-treated with trametinib]; CCND1 protein inhibits the reaction [BRAF protein mutant form results in increased susceptibility to dabrafenib]; fatostatin affects the reaction [BRAF protein affects the susceptibility to [dabrafenib co-treated with trametinib]]; MAPK1 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to dabrafenib]; MAPK3 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to dabrafenib] | PMID:26978007 PMID:29950559 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |